Phase III lipid-lowering studies of bococizumab meet primary endpoints

US pharma giant Pfizer (NYSE: PFE) has announced two additional Phase III bococizumab trials, SPIRE-HR (High Risk) and SPIRE-FH (Familial Hypercholesterolemia), met their primary endpoint, demonstrating a significant reduction in the percent change from baseline in low-density lipoprotein cholesterol (LDL-C) at 12 weeks compared to placebo among adults at high and very high risk for cardiovascular events who were receiving a maximally tolerated dose of a highly effective statin.

Pfizer shares edged 1.9% higher to $34.44 on Tuesday, as Wall Street started bouncing back after two days of declines following the UK’s Brexit vote.

SPIRE-HR and SPIRE-FH are the third and fourth of six SPIRE lipid-lowering Phase III studies to complete and show positive results. The two remaining SPIRE lipid-lowering studies are anticipated to complete later in 2016. Both SPIRE-HR and SPIRE-FH continued for 52 weeks to assess the longer-term efficacy and safety of bococizumab, an investigational proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i), in patients at high and very high risk for cardiovascular events.